mycophenolate mofetil + dexamethasone

This is a combination of two pharmaceutical agents, mycophenolate mofetil and dexamethasone. Mycophenolate mofetil is a prodrug of mycophenolic acid and acts as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), leading to suppression of lymphocyte proliferation by inhibiting guanosine nucleotide synthesis. It is primarily used as an immunosuppressant to prevent organ transplant rejection and in the management of certain autoimmune diseases[2][6][7]. Dexamethasone is a potent synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties, acting mainly through activation of the glucocorticoid receptor to modulate gene expression and suppress immune responses. The combination may be used in clinical practice for enhanced or synergistic immunosuppression, such as in organ transplantation or severe autoimmune conditions where both T-cell inhibition (mycophenolate) and broad anti-inflammatory effects (dexamethasone) are desired[3][5]. This combination does not have a unique brand name formulation but may be co-administered under medical supervision.

Other names

MMF and Dexamethasone